Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

The Sinonasal Outcome Test - 22, Validated for Danish Patients

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Bibi Lange, Odense University Hospital
ClinicalTrials.gov Identifier:
NCT01254916
First received: December 6, 2010
Last updated: May 6, 2012
Last verified: May 2012

December 6, 2010
May 6, 2012
October 2008
March 2009   (final data collection date for primary outcome measure)
Reproducibility of Sinonasal Outcome test 22 [ Time Frame: From the time of fullfilling the first SNOT-22 to fullfilling the second SNOT-22 after 14 days ] [ Designated as safety issue: No ]
Reproducibility of Sinonasal Outcome test 22
Complete list of historical versions of study NCT01254916 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
The Sinonasal Outcome Test - 22, Validated for Danish Patients
The Sinonasal Outcome Test - 22, Validated for Danish Patients

Introduction: Chronic rhinosinusitis (CRS) is a significant health problem increasing in both incidence and prevalence. It calls into attention consensus about diagnosing, assessing symptoms and treatment of patients with CRS. Therefore a validated Danish measure of health-related quality of life in sinonasal disease is needed.

Method: The Sinonasal Outcome measure 22 (SNOT-22) was translated into Danish and reproducibility was evaluated by test-retesting 40 patients with CRS. The statistical analyses used, were Pearson´s correlation coefficient, Cronbach´s alfa, Kappa and Bland-Altman´s Plot. Reproducibility was also tested looking at subscales within the SNOT-22.

Result: The results show good internal correlation with Cronbach´s alfa at 0.83 in the initial test and 0.92 in the retest. Pearson was 0.70 (p<0.001) revealing good correlation between the initial scores and the retests scores. Kappa was calculated for each item with a mean value of 0.61 showing substantial agreement. Paired t-test revealed no significant difference in the subscales.

Conclusion: The Danish version of SNOT-22 is recommended for Danish clinicians and researches as a patient-reported measure of outcome in sino-nasal disorders such as rhinosinusitis and nasal polyposis.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Patients with chronic rhinosinusitis diagnosed by a medical doctor

Chronic Rhinosinusitis
Not Provided
Patients with chronic rhinosinusitis
Lange B, Thilsing T, Al-kalemji A, Baelum J, Martinussen T, Kjeldsen A. The Sino-Nasal Outcome Test 22 validated for Danish patients. Dan Med Bull. 2011 Feb;58(2):A4235.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
44
March 2009
March 2009   (final data collection date for primary outcome measure)

Inclusion Criteria: Persons diagnosed with Chronic Rhinosinusitis -

Exclusion Criteria: Change of treatment or acute change of symptoms due to common cold/influenza in the time between completing the test and the retest. If SNOT-score was very low. Persons who left before offered test or declined testing.

-

Both
15 Years to 75 Years
No
Contact information is only displayed when the study is recruiting subjects
Denmark
 
NCT01254916
Danish SNOT 22
Not Provided
Bibi Lange, Odense University Hospital
Odense University Hospital
Not Provided
Not Provided
Odense University Hospital
May 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP